StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a report published on Friday. The brokerage issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
Shares of BTX stock opened at $6.54 on Friday. Brooklyn ImmunoTherapeutics has a 52-week low of $6.35 and a 52-week high of $8.31. The stock has a market cap of $384.72 million, a PE ratio of -2.88 and a beta of 4.61. The firm’s 50 day moving average price is $2.62 and its two-hundred day moving average price is $1.51.
Brooklyn ImmunoTherapeutics Dividend Announcement
The firm also recently disclosed a monthly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, March 14th will be paid a $0.0862 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.03 dividend on an annualized basis and a yield of 15.81%. Brooklyn ImmunoTherapeutics’s payout ratio is presently -40.09%.
About Brooklyn ImmunoTherapeutics
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Featured Stories
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Compound Interest and Why It Matters When Investing
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What is MarketRank™? How to Use it
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What Are the U.K. Market Holidays? How to Invest and Trade
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
